Literature DB >> 19922242

Potentially pathogenic bacteria cultured from the sputum of stable asthmatics are associated with increased 8-isoprostane and airway neutrophilia.

Lisa G Wood1, Jodie L Simpson, Philip M Hansbro, Peter G Gibson.   

Abstract

Potential bacterial pathogens are found in the airways in several diseases that are associated with neutrophilic inflammation. The aim of this study was to characterize subjects with stable asthma, with no symptoms of respiratory infection, to assess whether key potentially pathogenic bacteria were present in significant quantities in the airways and to correlate this with the pattern of airway inflammation and oxidative stress. Subjects with stable asthma (n = 115) and healthy controls (n = 8) underwent clinical assessment, including hypertonic saline challenge combined with sputum induction. A significant load of potentially pathogenic bacteria (> 10(6) cfu/mL) was cultured from the sputum of 17 (15%) subjects with stable asthma and was associated with higher total cell counts, proportion and number of neutrophils, sputum IL-8 and 8-isoprostane concentrations. The role of bacteria in potentiating neutrophilic asthma warrants further investigation. Therapies such as antibiotic and antioxidant treatment may be most effective in this sub-group of patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19922242     DOI: 10.3109/10715760903362576

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  39 in total

1.  Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials. Bridging Clinical and Patient Perspectives.

Authors:  Salman Siddiqui; Loren C Denlinger; Stephen J Fowler; Praveen Akuthota; Dominick E Shaw; Liam G Heaney; Louise Brown; Mario Castro; Tonya A Winders; Monica Kraft; Scott Wagers; Michael C Peters; Ian D Pavord; Samantha Walker; Nizar N Jarjour
Journal:  Am J Respir Crit Care Med       Date:  2019-04-01       Impact factor: 21.405

Review 2.  The Potential for Emerging Microbiome-Mediated Therapeutics in Asthma.

Authors:  Ayse Bilge Ozturk; Benjamin Arthur Turturice; David L Perkins; Patricia W Finn
Journal:  Curr Allergy Asthma Rep       Date:  2017-08-10       Impact factor: 4.806

3.  Does antimicrobial therapy improve outcomes in horses with severe equine asthma and a positive tracheal wash bacterial culture?

Authors:  Michelle L Husulak; Stephen T Manning; Melissa D Meachem; Hilary J Burgess; Tasha Y Epp; Julia B Montgomery
Journal:  Can J Vet Res       Date:  2018-07       Impact factor: 1.310

Review 4.  Defining phenotypes in asthma: a step towards personalized medicine.

Authors:  Kian Fan Chung
Journal:  Drugs       Date:  2014-05       Impact factor: 9.546

Review 5.  The immune response to Prevotella bacteria in chronic inflammatory disease.

Authors:  Jeppe Madura Larsen
Journal:  Immunology       Date:  2017-06-20       Impact factor: 7.397

Review 6.  Isoprostanes and asthma.

Authors:  Judith A Voynow; Apparao Kummarapurugu
Journal:  Biochim Biophys Acta       Date:  2011-05-08

7.  Early-Life Intranasal Colonization with Nontypeable Haemophilus influenzae Exacerbates Juvenile Airway Disease in Mice.

Authors:  Jessica R McCann; Stanley N Mason; Richard L Auten; Joseph W St Geme; Patrick C Seed
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

Review 8.  How variability in clinical phenotypes should guide research into disease mechanisms in asthma.

Authors:  Kian Fan Chung; Ian M Adcock
Journal:  Ann Am Thorac Soc       Date:  2013-12

9.  The Relationship Between Lower Respiratory Tract Microbiome and Allergic Respiratory Tract Diseases in Children.

Authors:  Jinghua Cui; Yuanyuan Zhang; Hanqing Zhao; Xuemei Sun; Zhen Chen; Qun Zhang; Chao Yan; Guanhua Xue; Shaoli Li; Yanling Feng; Han Liu; Xianghui Xie; Jing Yuan
Journal:  Front Microbiol       Date:  2021-05-14       Impact factor: 5.640

Review 10.  The Airway Microbiome-IL-17 Axis: a Critical Regulator of Chronic Inflammatory Disease.

Authors:  Jenny M Mannion; Rachel M McLoughlin; Stephen J Lalor
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-11       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.